Building better monoclonal antibody-based therapeutics
GJ Weiner - Nature Reviews Cancer, 2015 - nature.com
For 20 years, monoclonal antibodies (mAbs) have been a standard component of cancer
therapy, but there is still much room for improvement. Efforts continue to build better cancer …
therapy, but there is still much room for improvement. Efforts continue to build better cancer …
Bispecific antibodies: design, therapy, perspectives
SE Sedykh, VV Prinz, VN Buneva… - Drug design …, 2018 - Taylor & Francis
Antibodies (Abs) containing two different antigen-binding sites in one molecule are called
bispecific. Bispecific Abs (BsAbs) were first described in the 1960s, the first monoclonal …
bispecific. Bispecific Abs (BsAbs) were first described in the 1960s, the first monoclonal …
A novel carcinoembryonic antigen T-cell bispecific antibody (CEA TCB) for the treatment of solid tumors
M Bacac, T Fauti, J Sam, S Colombetti, T Weinzierl… - Clinical Cancer …, 2016 - AACR
Purpose: CEA TCB is a novel IgG-based T-cell bispecific (TCB) antibody for the treatment of
CEA-expressing solid tumors currently in phase I clinical trials (NCT02324257). Its format …
CEA-expressing solid tumors currently in phase I clinical trials (NCT02324257). Its format …
Improving the efficacy of antibody-based cancer therapies
P Carter - Nature Reviews Cancer, 2001 - nature.com
A quarter of a century after their advent, monoclonal antibodies have become the most
rapidly expanding class of pharmaceuticals for treating a wide variety of human diseases …
rapidly expanding class of pharmaceuticals for treating a wide variety of human diseases …
Bi-specific and tri-specific antibodies-the next big thing in solid tumor therapeutics
K Runcie, DR Budman, V John, N Seetharamu - Molecular Medicine, 2018 - Springer
Antibody-based therapy has revitalized the world of cancer therapeutics since rituximab was
first approved for the treatment of Non-Hodgkin's Lymphoma. Monoclonal antibodies against …
first approved for the treatment of Non-Hodgkin's Lymphoma. Monoclonal antibodies against …
Receptor tyrosine kinase signalling as a target for cancer intervention strategies.
E Zwick, J Bange, A Ullrich - Endocrine-related cancer, 2001 - erc.bioscientifica.com
In multicellular organisms, communication between individual cells is essential for the
regulation and coordination of complex cellular processes such as growth, differentiation …
regulation and coordination of complex cellular processes such as growth, differentiation …
Induction of regular cytolytic T cell synapses by bispecific single-chain antibody constructs on MHC class I-negative tumor cells
S Offner, R Hofmeister, A Romaniuk, P Kufer… - Molecular …, 2006 - Elsevier
Certain bispecific single-chain antibody constructs exhibit an extraordinary potency for
polyclonal T cell engagement and target cell lysis. Here we studied the structural basis for …
polyclonal T cell engagement and target cell lysis. Here we studied the structural basis for …
Extremely potent, rapid and costimulation‐independent cytotoxic T‐cell response against lymphoma cells catalyzed by a single‐chain bispecific antibody
T Dreier, G Lorenczewski, C Brandl… - … journal of cancer, 2002 - Wiley Online Library
A recent study reported on an anti-CD19/anti-CD3 singlechain bispecific antibody
(bscCD19xCD3) exhibiting high activity against human B lymphoma cell lines (Löffler et al …
(bscCD19xCD3) exhibiting high activity against human B lymphoma cell lines (Löffler et al …
Camel single-domain antibodies as modular building units in bispecific and bivalent antibody constructs
KE Conrath, M Lauwereys, L Wyns… - Journal of Biological …, 2001 - ASBMB
Single-domain antibodies against various antigens are isolated from the unique heavy-
chain antibodies of immunized camels and llamas. These minimal sized binders are very …
chain antibodies of immunized camels and llamas. These minimal sized binders are very …